American Journal of Clinical Dermatology

, Volume 10, Issue 1, pp 9–21 | Cite as


A Review
  • Tasneem Poonawalla
  • Brent KellyEmail author
Review Article


Urticaria is often classified as acute, chronic, or physical based on duration of symptoms and the presence or absence of inducing stimuli. Urticarial vasculitis, contact urticaria, and special syndromes are also included under the broad heading of urticaria. Recent advances in our understanding of the pathogenesis of chronic urticaria include the finding of autoantibodies to mast cell receptors in nearly half of patients with chronic idiopathic urticaria. These patients may have more severe disease and require more aggressive therapies. Extensive laboratory evaluation for patients with chronic urticaria is typically unrevealing and there are no compelling data that associate urticaria with chronic infections or malignancy. Pharmacologic therapy consists primarily of the appropriate use of first- and second-generation histamine H1 receptor antihistamines. Additional therapy may include leukotriene receptor antagonists, corticosteroids, and immunomodulatory agents for severe, unremitting disease. Despite our greater understanding of the pathogenesis of urticaria, the condition remains a frustrating entity for many patients, particularly those with chronic urticaria.


Urticaria Cetirizine Chronic Urticaria Desloratadine Chronic Idiopathic Urticaria 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Rook A. The historical background. In: Warin RP, Champion RH. Urticaria. London: Saunders, 1974: 1–9Google Scholar
  2. 2.
    Humphreys F. Major landmarks in the history of urticarial disorders. Int J Dermatol 1997; 36: 793–6PubMedCrossRefGoogle Scholar
  3. 3.
    Czarnetzki BM. The history of urticaria. Int J Dermatol 1989; 28 (1): 52–7PubMedCrossRefGoogle Scholar
  4. 4.
    Grattan C, Black AK. Urticaria and angioedema. In: Bolognia JL, Jorrizo JL, Rapini RP, editors. Dermatology. Vol. 1. London: Elsevier, 2003: 287–302Google Scholar
  5. 5.
    Greaves M. Chronic urticaria. J Allergy Clin Immunol 2000; 105: 664–72PubMedCrossRefGoogle Scholar
  6. 6.
    Schafer T, Ring I. Epidemiology of urticaria. In: Burr ML, editor. Epidemiology of clinical allergy: monographs in allergy. Basel: Karger, 1993: 49–60Google Scholar
  7. 7.
    Paul E, Greilich KD, Dominante G. Epidemiology of urticaria. Monogr Allergy 1987; 21: 87–115PubMedGoogle Scholar
  8. 8.
    Mortureux P, Leaute-Labreze C, Legrain-Lifermann V, et al. Acute urticaria in infancy and early childhood: a prospective study. Arch Dermatol 1998; 134: 319–23PubMedCrossRefGoogle Scholar
  9. 9.
    Grob J, Revuz J, Ortonne JP, et al. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005; 152: 289–95PubMedCrossRefGoogle Scholar
  10. 10.
    Dice JP. Physical urticaria. Immunol Allergy Clin North Am 2004; 24 (2): 225–46PubMedCrossRefGoogle Scholar
  11. 11.
    Lipsker D, Spehner D, Drillien R, et al. Schnitzler syndrome: heterogeneous immunopathological findings involving IgM-skin interactions. Br J Dermatol 2000; 142 (5): 954–9PubMedCrossRefGoogle Scholar
  12. 12.
    Saurat JH, Schifferli J, Steiger G, et al. Anti-interleukin-1 alpha autoantibodies in humans: characterization, isotype distribution, and receptor-binding inhibition: higher frequency in Schnitzler’s syndrome (urticaria and macroglobulinemia). J Allergy Clin Immunol 1991; 88 (2): 244–56PubMedCrossRefGoogle Scholar
  13. 13.
    Asli B, Bienvenu B, Cordoliani F, et al. Chronic urticaria and monoclonal IgM gammopathy (Schnitzler syndrome). Arch Dermatol 2007; 143 (8): 1046–50PubMedCrossRefGoogle Scholar
  14. 14.
    Kanazawa N, Furukawa F. Autoinflammatory syndromes with a dermatological perspective. J Dermatol 2007; 34: 601–18PubMedCrossRefGoogle Scholar
  15. 15.
    Matz H, Orion E, Wolf R. Pruritic urticarial papules and plaques of pregnancy: polymorphic eruption of pregnancy (PUPPP). Clin Dermatol 2006; 24: 105–8PubMedCrossRefGoogle Scholar
  16. 16.
    Jorrizo J. Approach to the chronic urticaria patient. Texas Dermatologic Society meeting; 2004 May 15; Austin (TX)Google Scholar
  17. 17.
    Wisnieski JJ. Urticarial vasculitis. Curr Opin Rheumatol 2000; 12: 24–31PubMedCrossRefGoogle Scholar
  18. 18.
    Hide M, Francis DM, Grattan CE, et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. New Engl J Med 1993; 328: 1599–604PubMedCrossRefGoogle Scholar
  19. 19.
    Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol 2003; 3: 363–8PubMedCrossRefGoogle Scholar
  20. 20.
    Venarske D, de Shazo RD. Molecular mechanisms of allergic disease. South Med J 2003; 96: 1049–54PubMedCrossRefGoogle Scholar
  21. 21.
    Buhner S, Reese I, Kuehl F, et al. Pseudoallergic reactions in chronic urticaria are associated with altered gastroduodenal permeability. Allergy 2004; 59: 1118–23PubMedCrossRefGoogle Scholar
  22. 22.
    Powell RJ, Du Toit GL, Siddique N, et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007; 37: 631–50PubMedCrossRefGoogle Scholar
  23. 23.
    Kaplan AP, Finn A. Autoimmunity and the etiology of chronic urticaria. Can J Allergy Clin Immunol 1999; 4: 286–92Google Scholar
  24. 24.
    Leznoff A, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol 1989; 84: 66–71PubMedCrossRefGoogle Scholar
  25. 25.
    O’Donnell BF, Francis DM, Swana GT, et al. Thyroid autoimmunity in chronic urticaria. Br J Dermatol 2005; 153: 331–5PubMedCrossRefGoogle Scholar
  26. 26.
    Bakos N, Hillander M. Comparison of chronic autoimmune urticaria with chronic idiopathic urticaria. Int J Dermatol 2003; 42: 613–5PubMedCrossRefGoogle Scholar
  27. 27.
    Zauli D, Grassi A, Ballardini G, et al. Thyroid autoimmunity in chronic idiopathic urticaria. Am J Clin Dermatol 2002; 3: 525–8PubMedCrossRefGoogle Scholar
  28. 28.
    Fusari A, Colangelo C, Bonifazi F, et al. The autologous serum skin test in the follow-up of patients with chronic urticaria. Allergy 2005; 60: 256–8PubMedCrossRefGoogle Scholar
  29. 29.
    Sabroe RA, Seed PT, Francis DM, et al. Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-Fc epsilon RI or anti-IgE autoantibodies. J Am Acad Dermatol 1999; 40: 443–50PubMedCrossRefGoogle Scholar
  30. 30.
    Asero R, Orsatti A, Tedeschi A, et al. Autoimmune chronic urticaria associated with type 1 diabetes and Graves’ disease. J Allergy Clin Immunol 2005; 115: 1088–9PubMedCrossRefGoogle Scholar
  31. 31.
    Hizal M, Tuzan B, Wolf R, et al. The relationship between Helicobacter pylori IgG antibody and autologous serum test in chronic urticaria. Int J Dermatol 2000; 39: 443–5PubMedCrossRefGoogle Scholar
  32. 32.
    Hook-Nikanne J, Varjonen E, Harvima RJ, et al. Is Helicobacter pylori infection associated with chronic urticaria? Acta Derm Venereol 2000; 80 (6): 425–6PubMedCrossRefGoogle Scholar
  33. 33.
    Federman DG, Kirsner RS, Moriarty JP, et al. The effect of antibiotic therapy for patients infected with Helicobacter pylori who have chronic urticaria. J Am Acad Dermatol 2003; 49: 861–4PubMedCrossRefGoogle Scholar
  34. 34.
    Magen E, Mishal J, Schlesinger M, et al. Eradication of Helicobacter pylori infection equally improves chronic urticaria with positive and negative autologous serum skin test. Helicobacter 2007; 12 (5): 567–71PubMedCrossRefGoogle Scholar
  35. 35.
    Baskan EB, Turker T, Gulten M, et al. Lack of correlation between Helicobacter pylori infection and autologous serum skin test in chronic idiopathic urticaria. Int J Dermatol 2005; 44 (12): 993–5PubMedCrossRefGoogle Scholar
  36. 36.
    Fukuda S, Shimoyama T, Umegaki N, et al. Effect of Helicobacter pylori eradication in the treatment of Japanese patients with chronic idiopathic urticaria. J Gastroenterol 2004; 39 (9): 827–30PubMedCrossRefGoogle Scholar
  37. 37.
    Kozel MM, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004; 64: 2515–36PubMedCrossRefGoogle Scholar
  38. 38.
    Grattan C, Powell S, Humphreys F, et al. Management and diagnostic guidelines for urticaria and angio-oedema. Br J Dermatol 2001; 144: 708–14PubMedCrossRefGoogle Scholar
  39. 39.
    Wedi B, Raap U, Kapp A. Chronic urticaria and infections. Curr Opin Allergy Clin Immunol 2004; 4: 387–96PubMedCrossRefGoogle Scholar
  40. 40.
    Daschner A, Vega de la Osada F, Pascual CY. Allergy and parasites reevaluated:wide-scale induction of chronic urticaria by the ubiquitous fish-nematode Anisakis simplex in an endemic region. Allergol Immunopathol (Madr) 2005; 33: 31–7CrossRefGoogle Scholar
  41. 41.
    Daschner A, Pascual CY. Anisakis simplex: sensitization and clinical allergy. Curr Opin Allergy Clin Immunol 2005; 5: 281–5PubMedCrossRefGoogle Scholar
  42. 42.
    Kanazawa K, Yaoita H, Tsuda F, et al. Hepatitis C virus infection in patients with urticaria. J Am Acad Dermatol 1996; 35: 195–8PubMedCrossRefGoogle Scholar
  43. 43.
    Cribier BJ, Santinelli F, Schmitt C, et al. Chronic urticaria is not significantly associated with hepatitis C or hepatitis G infection: a case control study. Arch Dermatol 1999; 135 (11): 1335–9PubMedCrossRefGoogle Scholar
  44. 44.
    Asero R. Chronic idiopathic urticaria: a family study. Ann Allergy Asthma Immunol 2002; 89: 195–6PubMedCrossRefGoogle Scholar
  45. 45.
    O’Donnell BF, O’Neill CM, Francis DM, et al. Human leucocyte antigen class II associations in chronic idiopathic urticaria. Br J Dermatol 1999; 140: 853–8PubMedCrossRefGoogle Scholar
  46. 46.
    Maxwell DL, Atkinson BA, Spur BW, et al. Skin responses to intradermal histamine and leukotrienes C4, D4, and E4 in patients with chronic idiopathic urticaria and in normal subjects. J Allergy Clin Immunol 1990; 86: 759–65PubMedCrossRefGoogle Scholar
  47. 47.
    Caproni M, Cardinali C, Giomi B, et al. Serological detection of eotaxin, IL-4, IL-13, IFN-gamma, MIP-1alpha, TARC and IP-10 in chronic autoimmune urticaria and chronic idiopathic urticaria. J Dermatol Sci 2004; 36: 57–9PubMedCrossRefGoogle Scholar
  48. 48.
    Caproni M, Giomi B, Volpi W, et al. Chronic idiopathic urticaria: infiltrating cells and related cytokines in autologous serum-induced wheals. Clin Immunol 2005; 114: 284–92PubMedCrossRefGoogle Scholar
  49. 49.
    Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004; 114: 465–74PubMedCrossRefGoogle Scholar
  50. 50.
    Kessel A, Bishara R, Amital A, et al. Increased plasma levels of matrix metal-loproteinase-9 are associated with the severity of chronic urticaria. Clin Exp Allergy 2005; 35: 221–5PubMedCrossRefGoogle Scholar
  51. 51.
    Tedeschi A, Lorini M, Asero R. No evidence of increased serum substance P levels in chronic urticaria patients with and without demonstrable circulating vasoactive factors. Clin Exp Derm 2005; 30: 171–5PubMedCrossRefGoogle Scholar
  52. 52.
    Kikuchi Y, Kaplan AP. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol 2002; 109: 114–8PubMedCrossRefGoogle Scholar
  53. 53.
    Soundararajan S, Kikuchi Y, Joseph K, et al. Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria. J Allergy Clin Immunol 2005; 115: 815–21PubMedCrossRefGoogle Scholar
  54. 54.
    Asero R, Madonini E. Bronchial hyperresponsiveness is a common feature in patients with chronic urticaria. J Invest Allerg Clin Immunol 2006; 16 (1): 19–23Google Scholar
  55. 55.
    Sabroe RA, Francis DM, Barr RM, et al. Anti-FcεRI autoantibodies and basophil histamine releasability in chronic idiopathic urticaria. J Allergy Clin Immunol 1998; 102: 651–8PubMedCrossRefGoogle Scholar
  56. 56.
    Kaplan AP, Joseph K, Shibayama Y, et al. Bradykinin formation: plasma and tissue pathways and cellular interactions. In: Gallin J, Snyderman R, editors. Inflammation: basic principles and clinical correlates. 3rd ed. Philadelphia (PA): Lippincott, Williams and Wilkins, 1999: 331–47Google Scholar
  57. 57.
    Schaeffer RC, Gong F, Bitrick MS, et al. Thrombin and bradykinin initiate discrete endothelial solute permeability mechanisms. Am J Physiol 1993; 264: 1798–809Google Scholar
  58. 58.
    Asero R, Tedeschi A, Riboldi P, et al. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol 2006; 117 (5): 1113–7PubMedCrossRefGoogle Scholar
  59. 59.
    Kozel MM, Moein MC, Mekkes JR, et al. Evaluation of a clinical guideline for the diagnoses of physical and chronic urticaria and angioedema. Acta Derm Venereol 2002; 82: 270–4PubMedCrossRefGoogle Scholar
  60. 60.
    Kozel MM, Mekkes JR, Bossuyt PM, et al. The effectiveness of a history-based diagnostic approach in chronic urticaria and angioedema. Arch Dermatol 1998; 134: 1575–80PubMedCrossRefGoogle Scholar
  61. 61.
    Kozel MM, Bossuyt PM, Mekkes JR, et al. Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: a systematic review. J Am Acad Dermatol 2003; 48: 409–16PubMedCrossRefGoogle Scholar
  62. 62.
    Grattan CE, Walpole D, Francis DM, et al. Flow cytometric analysis of basophil numbers in chronic urticaria: basopenia is related to serum histamine releasing activity. Clin Exp Allergy 1997; 27: 1417–24PubMedCrossRefGoogle Scholar
  63. 63.
    Grattan CE, Dawn G, Gibbs S, et al. Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity. Clin Exp Allergy 2003; 33: 337–41PubMedCrossRefGoogle Scholar
  64. 64.
    Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32: 489–98PubMedCrossRefGoogle Scholar
  65. 65.
    Thomson L, Blaylock MG, Sexton DW, et al. Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. Clin Exp Allergy 2002; 32: 1187–92PubMedCrossRefGoogle Scholar
  66. 66.
    Gillard M, Strolin Benedetti M, Chatelain P, et al. Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Inflamm Res 2005; 54: 367–9PubMedCrossRefGoogle Scholar
  67. 67.
    Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Dermatol 2006; 32: 34–8Google Scholar
  68. 68.
    Kaplan AP, Spector SL, Meeves S, et al. Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 2005; 95: 662–9CrossRefGoogle Scholar
  69. 69.
    Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2000; 84: 517–22PubMedCrossRefGoogle Scholar
  70. 70.
    Henz BM. The pharmacologic profile of desloratadine: a review. Allergy 2001; 56 Suppl. 65: 7–13PubMedCrossRefGoogle Scholar
  71. 71.
    Breneman DL. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. Ann Pharmacother 1996; 30: 1075–9PubMedGoogle Scholar
  72. 72.
    Kapp A, Wedi B. Chronic urticaria: clinical aspects and focus on a new antihistamine, levocetirizine. J Drugs Dermatol 2004; 3: 632–9PubMedGoogle Scholar
  73. 73.
    Harvey RR, Wegs J, Schocket AL. A controlled trial of therapy in chronic urticaria. J Allergy Clin Immunol 1981; 68: 262–6PubMedCrossRefGoogle Scholar
  74. 74.
    Tedeschi A, Airaghi L, Lorini M, et al. Chronic urticaria: a role for newer immunomodulatory drugs. Am J Clin Dermatol 2003; 4: 297–305PubMedCrossRefGoogle Scholar
  75. 75.
    Hannuksela M, Kokkonen EL. Ultraviolet light therapy in chronic urticaria. Acta Derm Venereol 1985; 65: 449–50PubMedGoogle Scholar
  76. 76.
    Greene SL, Reed CE, Schroeter AL. Double-blind crossover study comparing doxepin with diphenhydramine for the treatment of chronic urticaria. J Am Acad Dermatol 1985; 12: 669–75PubMedCrossRefGoogle Scholar
  77. 77.
    Goldsobel AB, Rohr AS, Siegel SC, et al. Efficacy of doxepin in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1986; 78 (5 Pt 1): 867–73PubMedCrossRefGoogle Scholar
  78. 78.
    Thormann H, Bindslev-Jensen C. Mirtazapine for chronic urticaria. Acta Derm Venereol 2004; 84: 482–3PubMedGoogle Scholar
  79. 79.
    Kaplan AP. Chronic urticaria and angioedema. New Engl J Med 2002; 346: 175–9PubMedCrossRefGoogle Scholar
  80. 80.
    Ellis MH. Successful treatment of chronic urticaria with leukotriene antagonists. J Allergy Clin Immunol 1998; 102: 876–7PubMedCrossRefGoogle Scholar
  81. 81.
    Spector S, Tan RA. Antileukotrienes in chronic urticaria [letter]. J Allergy Clin Immunol 1998; 102 (4 Pt 1): 572Google Scholar
  82. 82.
    Asero R, Tedeschi A, Lorini M. Leukotriene receptor antagonists in chronic urticaria. Allergy 2001; 56: 456–7PubMedCrossRefGoogle Scholar
  83. 83.
    Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 2002; 110: 484–8PubMedCrossRefGoogle Scholar
  84. 84.
    Asero R. Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. Ann Allergy Asthma Immunol 2000; 85: 156–7PubMedCrossRefGoogle Scholar
  85. 85.
    Nettis E, Colanardi MC, Paradiso MT, et al. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2004; 34: 1401–7PubMedCrossRefGoogle Scholar
  86. 86.
    Bagenstose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol 2004; 113: 134–40PubMedCrossRefGoogle Scholar
  87. 87.
    Reimers A, Pichler C, Helbling A, et al. Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Clin Exp Allergy 2002; 32: 1763–8PubMedCrossRefGoogle Scholar
  88. 88.
    Bressler RB, Sowell K, Huston DP. Therapy of chronic idiopathic urticaria with nifedipine: demonstration of beneficial effect in a double-blinded, placebo-controlled, crossover trial. J Allergy Clin Immunol 1989; 83 (4): 756–63PubMedCrossRefGoogle Scholar
  89. 89.
    Di Gioacchino M, Di Stefano F, Cavallucci E, et al. Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation. Allergy Asthma Proc 2003; 24: 285–90PubMedGoogle Scholar
  90. 90.
    Grattan CE, O’Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Br J Dermatol 2000; 143: 365–72PubMedCrossRefGoogle Scholar
  91. 91.
    Stanaland BE. Treatment of patients with chronic idiopathic urticaria. Clin Rev Allergy Immunol 2002; 23: 233–41PubMedCrossRefGoogle Scholar
  92. 92.
    Bernstein JA, Garramone SM, Lower EG. Successful treatment of autoimmune chronic idiopathic urticaria with intravenous cyclophosphamide. Ann Allergy Asthma Immunol 2002; 89: 212–4PubMedCrossRefGoogle Scholar
  93. 93.
    Gach JE, Sabroe RA, Greaves MW, et al. Methotrexate-responsive chronic idio-pathic urticaria: a report of two cases. Br J Dermatol 2001; 145: 340–3PubMedCrossRefGoogle Scholar
  94. 94.
    Shahar E, Bergman R, Guttman-Yassky E, et al. Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids. Int J Dermatol 2006; 45: 1224–7PubMedCrossRefGoogle Scholar
  95. 95.
    Klote MM, Nelson MR, Engler RJ. Autoimmune urticaria response to high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2005; 94: 307–8PubMedCrossRefGoogle Scholar
  96. 96.
    O’Donnell BF, Barr RM, Black AK, et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 1998; 138: 101–6PubMedCrossRefGoogle Scholar
  97. 97.
    Asero R. Are IVIg for chronic unremitting urticaria effective? Allergy 2000; 55: 1099–101PubMedCrossRefGoogle Scholar
  98. 98.
    Grattan CE, Francis DM, Slater NG, et al. Plasmapheresis for severe, unremitting, chronic urticaria. Lancet 1992; 339: 1078–80PubMedCrossRefGoogle Scholar
  99. 99.
    Boehm I, Bauer R, Bieber T. Urticaria treated with dapsone. Allergy 1999; 54: 765–6PubMedCrossRefGoogle Scholar
  100. 100.
    Cassano N, D’Argento V, Filotico R, et al. Low-dose dapsone in chronic idiopathic urticaria: preliminary results of an open study. Acta Derm Venereol 2005; 85: 254–5PubMedGoogle Scholar
  101. 101.
    Reeves GE, Boyle MJ, Bonfield J, et al. Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J 2004; 34: 182–6PubMedCrossRefGoogle Scholar
  102. 102.
    Berth-Jones J, Hutchinson PE, Wicks AC, et al. Chronic urticaria with angio-oedema controlled by warfarin. BMJ 1988; 297: 1382–3PubMedCrossRefGoogle Scholar
  103. 103.
    Parslew R, Pryce D, Ashworth J, et al. Warfarin treatment of chronic idiopathic urticaria and angio-oedema. Clin Exp Allergy 2000; 30: 1161–5PubMedCrossRefGoogle Scholar
  104. 104.
    Barlow RJ, Greaves MW. Warfarin in the treatment of chronic urticaria/angio-edema. Br J Dermatol 1992; 126: 415–6PubMedCrossRefGoogle Scholar
  105. 105.
    Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007; 99: 90–3CrossRefGoogle Scholar
  106. 106.
    Gimenez-Arnau A, Pujol RM, Ianosi S, et al. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study. Allergy 2007; 62 (5): 539–46PubMedCrossRefGoogle Scholar
  107. 107.
    Dunford PJ, Williams KN, Desai PJ, et al. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol 2007; 119 (1): 176–83PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.University of Texas Medical BranchGalvestonUSA

Personalised recommendations